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Background: Universal access to effective treatments is a goal of the Roll Back Malaria Partnership. However,
despite official commitments and substantial increases in financing, this objective remains elusive, as development
assistance continue to be routed largely through government channels, leaving the much needed highly effective
treatments inaccessible or unaffordable to those seeking services in the private sector.
Methods: To quantify the effect of price disparity between the government and private health systems, this study
have audited 92 government and private Drug Selling Units (DSUs) in Morogoro urban district in Tanzania to
determine the levels, trend and consumption pattern of antimalarial drugs in the two health systems. A
combination of observation, interviews and questionnaire administered to the service providers of the randomly
selected DSUs were used to collect data.
Results: ALU was the most selling antimalarial drug in the government health system at a subsidized price of 300
TShs (0.18 US$). By contrast, ALU that was available in the private sector (coartem) was being sold at a price of
about 10,000 TShs (5.9 US$), the price that was by far unaffordable, prompting people to resort to cheap but failed
drugs. As a result, metakelfin (the phased out drug) was the most selling drug in the private health system at a
price ranging from 500 to 2,000 TShs (0.29–1.18 US$).
Conclusions: In order for the prompt diagnosis and treatment with effective drugs intervention to have big impact on
malaria in mostly low socioeconomic malaria-endemic areas of Africa, inequities in affordability and access to effective
treatment must be eliminated. For this to be ensued, subsidized drugs should be made available in both government
and private health sectors to promote a universal access to effective safe and affordable life saving antimalarial drugs.Background
Prompt treatment with effective antimalarial drugs is
among major strategies for control of the life-threatening
malaria disease. However, the success of this strategy faces
daunting challenges of spread of drug resistance and im-
pediment of access to effective treatment for malaria [1].
Development assistance has been routed largely through
government channels, whereas affected individuals seek* Correspondence: amalisa@suanet.ac.tz
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medium, provided the original work is properly ctreatment mostly through the private sector and the new
artemisinin-based combination treatments (ACTs), recom-
mended by WHO for uncomplicated falciparum malaria,
are too expensive for many people who seek treatment in
the private sector [1]. Although it is widely recognized
that, the government health sector plays a central role in
the delivery of key curative and preventive interventions
for malaria in most African countries, government sector
alone do not guarantee sufficient levels of access in malaria
endemic countries [2]. Evidence from surveys conducted
between 2007 and 2008 in 11 countries across Africa
indicates that despite large increase in the number oftral Ltd. This is an Open Access article distributed under the terms of the Creative Commons
/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any
ited.
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health sector, only 15% of children with fever were treated
with ACTs [3].
Treatment of malaria in Tanzania is typically guided by
official recommendations from the Ministry of Health
and Social Welfare (MOHSW) regarding drugs of choice
for various situations. “First-line” treatment refers to the
drug officially recommended as the drug of first choice
for the treatment of uncomplicated malaria. “Second-
line” treatment refers to the drug officially recommended
as an alternative primarily to be used for treatment of
patients in whom the first-line treatment failed to clear
the infection and other select patients (such as those
who are hypersensitive to the first-line treatment).
“Third-line” treatment typically refers to the drug
recommended for severely ill patients (a rescue drug). In
practice, few treatment failures are recognized and
patients are often moved directly from first to third-line
treatment, consequently, little second-line drug is used
compared to the first-line drug. Tanzania changed her
antimalarial policy for the first time in 2001, when CQ
first line was replaced by SP as an interim first line
policy, while evaluating a long term solution. In 2006, SP
was replaced with Artemether + Lumefantrine (ALU)
combination therapy as the newly adopted first line anti-
malarial option for Tanzania [4]. At an ex-manufacturer
price of up to 11 US dollars (USD) per adult treatment
course, ACTs are 20–40 times more expensive than con-
ventional antimalarial medicines [1,5]. The adoption of
ACTs by malaria endemic countries has been made
possible largely because of an increased financial support
provided by the global fund to fight AIDS, Tuberculosis
and Malaria (GFATM). Newer initiatives to support
malaria control such as the US president’s Malaria initia-
tive (PMI) and the World Bank Booster Program which
were launched in 2005 are additional sources of support
for this change, but until now, their financial disburse-
ments have been considerably less than those of the
GFATM [6]. The advent of the Affordable Medicines
Facility for malaria (AMFm) in 2010 however, is destined
to supersede initial schemes providing opportunity for
up scaling to make ACT affordable and accessible [2].
AMFm is a financing mechanism designed to subsidize
the most effective anti-malaria drugs, ACTs; Tanzania
being among the 10 countries invited to pilot a first
phase of this subsidy as from mid 2010. Through co-
payment and subsidy; first-line buyers, including in-
country private sector wholesalers, hospitals and NGOs,
will pass on the benefit to patients who will pay a price of
$0.20–0.50 for ACTs, a price which is comparable to what
they are currently paying for less-effective alternatives.
This unique partnership is using innovative technology
to reduce the cost of ACTs which are still beyond the
reach of the world’s poorest people, thereby makingthese life-saving therapies more accessible to people in
the developing world.
The supply of subsidized ACTs in Tanzania is chan-
neled through the government health sector at an afford-
able price of 300 TShs (0.18 US$). Until recently, ALU
were only available in government health facilities.
Recently, however, few drug selling outlets branded as
Accredited Drug Distribution Outlets (ADDO) also
known as “duka la dawa baridi” are being evaluated and
will be licensed to sell the subsidized ALU, but it is still
under pilot study. Review of available literature reveal
that drug shops and pharmacies are often preferred to
health facilities as a first treatment action [2]. Some of
attributes making retailers more preferred include their
tendency to be more accessible, quick services, have
longer and more flexible opening hours, are willing to
negotiate charges and offer credits, are more polite and
friendlier and are generally perceived as being cheaper.
Not withstanding, government health facilities experi-
ence frequent stockouts leaving no option to patient
other than private drug shops and outlets. Since the
ACTs that are available in the private health sector are
not subsidized, their prices ranges from 10,000 to 15,
000 TShs (5.9–8.8 US$) which is approximately 30–50
times more expensive than those sold in the government
health sector. These prices are by far unaffordable by an
average Tanzanian citizen, prompting them to resort to
using inexpensive but failing drugs such as, CQ, AQ or
SP. Alternatively, some patients may use artemisinin
monotherapies, which are generally cheaper than ACTs
but could accelerate the development of parasite resist-
ance as has been suggested elsewhere [7,8]. Although
WHO discourages the use of artemisinins in monothe-
apy form, in the new era of ACTs, there is a concern that
medicine sellers will continue to sell artemisinin deriva-
tives alone (monotherapies), potentially jeopardizing
ACT efficacy in the long-term [9]. Despite this concern,
adequate data on levels/trends of use and prices of ACTs
in both the private and government health systems
continue to be lacking. The present study audited both
government and private DSUs in Morogoro urban dis-
trict to assess the implication of price on the availability
and use pattern of ACTs in the private sector.
Methods
Study area
The study was conducted in Morogoro Urban District
between January and April 2010, specifically involving
government and private health facilities (hospital, health
centre and dispensary), pharmacies and drug stores
(“duka la dawa baridi”) located at different parts of the
District. For the purpose of this study, government and
private health facilities, pharmacies and drug selling
stores/shops and outlets are hereby referred to as drug
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ferred here as the government drug selling unit (GDSU)
and private drug selling unit (PDSU), respectively. The
study area spans a total of 260 Km2, which is about
0.4% of 72,939 Km2 total area of Morogoro Region.
Plasmodium falciparum malaria transmission in the
study area is intense (with an estimated entomological
inoculation rate of 367 infectious bites per person per
year [10] and perennial with some seasonal fluctuation
(although recent studies indicate decrease in malaria
transmission in endemic areas but new entomological
inoculation rate for the studied area has not been
determined).
According to the National population census of 2002,
Morogoro municipal had a population of 235,000 people
and an average population growth rate of 4.6% [11].
Morogoro Urban has diverse ethnicity in which Luguru
and Pogoro being the majority are located across the
municipality, while other ethnic groups who identifies
themselves as Wachaga, Wasukuma, Wapare, Wanyakyusa,
Wahaya, Wahehe, Wasambaa, Wangoni and many others
are also found in substantial numbers. Major religions are
Christianity and Islam. Major economic activities in the
study area include trade (both retail and wholesale),
commercial and subsistence urban farming and employ-
ment in both government and private sector. The area is
served by 3 government hospitals (one of them is the
Morogoro regional referral hospital), 9 health centres (4
government and 5 private), 32 dispensaries (20 govern-
ment and 12 private), 14 private pharmacies and 118
private medical stores (duka la dawa baridi) (Table 1).
The study involved physical visit to the ascribed drug
selling units located in Morogoro Municipality to collect
data on levels and trends in price, availability and con-
sumption of antimalarials in Morogoro urban. A total of
92 DSUs (14 GDSUs and 78 PDSUs) were randomly
visited and questionnaire interviews administered to the
service providers.
Study method and data collection
The study employed stratified random sampling to in-
clude both GDSUs and PDSUs and for each, to includeTable 1 Number and categories of drug selling units
(government and private) serving the Morogoro Urban
District
S/N Drug selling unit category Government Private
1 Hospital 3 0
2 Health centre 4 5
3 Dispensary 20 12
4 Pharmacy 0 14
5 Medical store (duka la dawa baridi) 0 118
Total 27 149all categories of DSU where applicable (hospital, health
center, dispensary, pharmacy and drug shop or “duka la
dawa baridi”). The inclusion criteria were; any unit
within the study area stocking and selling antimalarial
drugs and willingness to consent and participate in the
study. Sample size of 92 DSUs was calculated using sam-
ple size calculator [12] from 176 DSUs serving the region
(Table 1) at a confidence interval and level of 95% and 7,
respectively. A combination of observation, interviews
and questionnaire administered to the service providers
of the DSUs, were used to collect data. Quantitative data
was collected using interviewer-administered question-
naires that were administered to all health providers of
the randomly selected DSUs including 14 government (2
hospitals, 2 health centres and 10 dispensaries) and 78
private (3 health centres, 6 dispensaries, 7 pharmacies
and 62 medical stores). The questionnaires focused on
research questions to assess the type and rate of antimal-
arial consumption between GDSUs and PDSUs and price
and availability of ACTs between the two sectors. Few
social-demographic data including age, religion, sex and
education was included in the questionnaires. An inter-
view guide comprising of 17 open-ended questions in Ki-
swahili was pre-tested on a sample of six drug store
service providers who were drawn from the original sam-
pling frame. Their responses, which were not included in
the final data analysis, were reviewed and the questions
refined in light of the pre-test. Detailed interviews were
then completed with 92 DSUs providers.
Data analysis
The quantitative data from primary source was edited
and coded. The hand sheets were prepared and data
entered into a computer using Microsoft Excel. Data
analysis was done using Statistical Package for Social
Science (SPSS) software and results generated in fre-
quency tables. Microsoft Excel was used to generate
histograms.
Ethics approval
Institutional clearance of the research was sought from
Sokoine University and consent was obtained from parti-
cipants before interview.
Results
Of the 92 respondents, 50% were aged between 15 and
30 years, 30.5% were between 31 and 45 years of age,
15.2% were between 46 and 60 years of age and the
remaining 4.3% were above 60 years old. In terms of sex,
67.4% were females while 32.6% were males. The spe-
cialty of respondents indicated that out of 92 respon-
dents, majority (52.2%) were nurses, 19.6% were doctors,
15.2% were pharmacists and 13.0% were drug sellers
(Table 2).
Table 2 Social demographic information of the
respondents (N= 92)
Variable Response Number (%)
Sex Male 30 (32.6)
Female 62 (67.4)




Specialty Nurse 48 (52.2)
Doctor 18 (19.6)
Pharmacist 14 (15.2)
Drug seller 12 (13.0)
Education level Primary education 10 (10.9)
Secondary education 48 (52.2)
Advanced level education 4 (4.3)
College/University education 30 (32.6)
Marital status Married 52 (56.5)
Single 36 (39.1)
Divorced 4 (4.3)
Religion Muslim 16 (17.4)
Christian 76 (82.6)
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10.9% had primary education, 52.2% had secondary edu-
cation, 4.3% had advanced education and the remaining
32.6% had college/University education. Marital status of
respondents suggested that 56.5% were married, 39.1%
were single while the remaining 4.3% were divorced. Ma-
jority (82.6%) of the respondents were Christians and the
remaining 17.4% were Muslims (Table 2).
Levels of awareness of first line drug for treatment of
malaria in Tanzania
A total of 92 DSUs in Morogoro urban, of which 78 were
private and 14 government, were surveyed. Eighteen (18)
different antimalarial drugs were being sold in the 92 vis-
ited DSUs in Morogoro municipal (Figure 1). The PDSUs
were the most diverse, as they were selling all the eight-
een (18) varieties of antimalarials available at Morogoro
municipal (Figure 1 B), while the GDSUs were less di-
verse, selling only six (6) varieties, which were a subset
of those sold in PDUs (Figure 1 A). The respondents to
the questionnaire administered to the visited DSUs were
the service providers. The respondents were asked
whether they know the nationally approved first line
antimalarial treatment. As expected, all the service provi-
ders of the GDSUs indicated they know, and correctly
mentioned ALU (Artemether + Lumefantrine) is the
approved drug. Since the GDSUs were composed of
health facilities only (hospitals, health centres anddispensaries), drug dispensing were done only after
prescription from medical doctor or a clinical officer,
and hence in the present study, detailed assessment of
awareness of the national antimalarial policy focused
mainly to PDSUs (Table 3).
Out of 78 respondents from PDSUs, 97.5% indicated
to know the first line drug, while only 2.5% respondents
indicated to be unaware. When required to mention the
approved first line national antimalaria treatment drug,
97.4% of the respondents who indicated to know it,
mentioned correctly ALU (Artemether + Lumefantrine-
92%) or CoartemW(Artmether + Lumefantrine-8%) while
2.6% mentioned wrongly MetakelfinW (Sulfamethoxypyr-
azine + Pyrimethamne). The respondents were also
requested to comment on proportions of customers visit-
ing the drug selling units, either with prescription from
medical doctor or to seek expert advice from PDSUs’
service providers, as compared to those who visit to
purchase without doctor’s prescription or the need for
expert advice. Sixty percent (60%) indicated majority to
moderate, while 40% indicated few numbers of custo-
mers purchase without prescription or consultation.
The respondents were also asked to list the most sell-
ing (preferred) drugs for malaria treatment in their order
of preference. The order of preference and the number
of times the drug was mentioned by different respon-
dents were harmonized into a percentage score (Figure 1
B). Surprisingly, metakelfin was the most selling drug
with a score of 17%, followed by quinine (12%), amodia-
quine (10%) and duo-cotecxin (9%). ALU, the nationally
recommended first line antimalarial drug ranked the fifth
similar to fansidar and SP each with a sore of 8%. Orodar
and artequick ranked the sixth, each scoring 5%, arte-
quine scored 4% and ranked the seventh and co-malafin
scored 3% and ranked eighth. Malafin, Arco, cotecxin
and Coartem scoring 2% each, ranked ninth, artesunate
and co-arinate each scoring 1% ranked tenth and CQ
and halfan scored 0.1 each and ranked eleventh. It was
also observed that, the number of PDSUs selling coartem
(the ALU substitute in the private sector) were concen-
trated in the urban centre and as you move away toward
the peri urban areas, the number decreased gradually.
However, in the GDSUs, as expected, ALU was the
most selling drug scoring 25%, quinine the second scor-
ing 21%, SP the third scoring 17%, artesunate the fourth
scoring 15.5%, amodiaquine the fifth scoring 12.5% and
metakelfin the sixth scoring 8% (Figure 1 A).
When the respondents were asked to give their
opinion on what determines consumer choices, 87%
mentioned price and efficacy of the drug, 10% mentioned
popularity of the drug and 3% mentioned other factors.
When required to specify the other factors determining
buyer’s choice they mentioned absence of adverse drug
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Figure 1 Customers’ preference for antimalarial drugs in Morogoro urban. A is GDSUs and B is PDSUs.
Malisa and Kiriba BMC Research Notes 2012, 5:165 Page 5 of 9
http://www.biomedcentral.com/1756-0500/5/165period of dosage completion (such as those taken only
once, e. g. metakelfin) are more preferred.
The subsidized artemether + lumefantrine (ALU) were
meant to be distributed and hence sold solely in the
government health system and therefore, for easier difer-
entiation from other drug preparations they were ordered
from a single manufacturer, Novartis, Switzerland in a
special and unique blister preparation. To confirm the
absence of subsidized ALU from PDSUs, we asked the
respondents whether their units were selling unauthorizedTable 3 Awareness of the national antimalarial policy and
factors influencing antimalarial consumption in the
private health sector (N= 78)
Variable Response Number (%)
Awareness of 1st line drug Aware 76 (97.5)
Unaware 2 (2.5)








Factors influencing drug choice Price and efficacy 68 (87.0)
Drug popularity 8(10.0)
Others 2 (3.0)ALU or not. Of the 78 PDSUs studied, 31% were selling
unauthorized ALU while 69% were not. Of the 24 units
found selling unauthorized ALU, 50.0% of them were sell-
ing it at large to moderate scale (quantities) while the other
50.0% were selling at a low scale (quantities).
Antimalarial drugs prices
The results of the survey of antimalarial drugs prices
in Morogoro municipal are shown in Figure 2. The
data shows a big difference in prices between the
PDSUs and GDSUs (See Figure 2). The GDSUs sold
only six varieties of antimalarial drugs, which were a
subset of the eighteen (18) varieties found in the
PDSUs at an affordable price range between 300 and
1,000 TShs (0.18–0.59 US$). To the contrary, the
PDSUs in Morogoro urban district, beside their diver-
sity in terms of stocking and selling 18 varieties of
antimalarial drugs, it revealed an amazing diverse list
of different prices for a single variety of drug (Figure 2
B). Quinine and fansidar, for instance, each had 7
different prices, with prices ranging from 200 to 4,500
TShs (0.12–2.64 US$) and 500–3,000 TShs (0.29–1.76
US$), respectively. The spectrum of different prices
for the same antimalarial drug variety compelled the
researcher to conduct a verbal interview with the
PDSUs service providers. When providers were asked,
what was the reason for one antimalarial variety to
have up to seven different prices?; this is what they





































































































































Figure 2 Price range of antimalarial drugs in Morogoro urban. A is for government and B is for private health sector. Note that some drugs
like fansidar had 7 different prices across the surveyed DSUs in the study area.
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the seller to fix a price of choice, but, two, lack of strict
enforcement of importation regulations leading to porous
national boundaries allowing the infiltration of all possible
drug generics from across the world that includes
quality and low quality alternatives, hence widely di-
vergent prices”. In general, there was a big difference
in terms of antimalarial drug prices between GDSUs
and PDSUs. The recommended first line antimalarial
treatment in Tanzania ALU for instance, had a price
of 300 TShs (0.18 US$) in the GDSUs compared to
its substitute Coartem in PDSUs sold at 13,000 TShs
(7.7 US$) p< 0.0001, and this difference was highly
statistically significant.Discussion and conclusions
This study has generated data on levels, trends of use
and prices of ACTs in both the PDSUs and GDSUs in
Morogoro Urban District in Tanzania. The information
generated is useful in several ways; firstly it provides the
understanding of the level of uptake of the national anti-
malarial guideline, giving an indication of the fraction of
the population that is accessible to effective, safe and life
saving drugs (ACTs); secondly, it provides field data on
the effect of high cost in, not only limiting access/afford-
ability of ACTs, but also subjecting those who are in
need of them to resort to cheap but failing alternative
drugs such as CQ and SP generics. The study also
reports the findings of competence and awareness of the
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(GDSUs) and private (PDSUs) in the study area. The
World Health Organisation (WHO) first endorsed ACTs
for the treatment of malaria in 2004 and recommended a
switch to ACTs as the first line malaria treatment in
2005 [13]. Subsequent to the endorsement, in January
2006, WHO made a strong appeal to pharmaceutical
companies, National Drug Regulatory Authorities and
international funding and procurement agencies to
manufacture, procure and promote ACTs as the best
standard of care for malaria treatment and called for an
end to the deployment of artemisinin monotherapies for
the treatment of uncomplicated malaria (a practice
especially common in the private sector) to prevent the
development of resistance to artemisinins [5].
The study found a very distinct consumption pattern
of antimalarial treatments between the government
health system and the private health system. In the gov-
ernment health system ALU (a nationally recommended
first line treatment) was the most selling drug followed
by quinine. On the contrast, in the private system, meta-
kelfin (sulfamethoxypyrazine + pyrimethamine) (a failed
drug that was replaced by ALU in the 2006 antimalarial
policy review) was the most selling drug followed by
quinine as in the government sector. However, this find-
ing is not surprising, given the price of coartem (a
substitute of ALU in PDSUs) which goes up to 13,000
TShs (7.7 US$) per adult dose, a price that is more than
40 times the price of ALU (300 TShs or 0.18 US$) in the
GDSUs. This finding is consistent with recent baseline
study of the private market for antimalarials in Muheza
town reporting SP to be the most consumed drug with
consumption rate of 74%, followed by AQ (13%), quinine
(11%) and ACT (2%) [14].
Since policy change from SP first line to ALU in 2006,
the supply of subsidized ALU in Tanzania has been solely
through government system until recently, when
Ministry of Health and Social Welfare (MOHSW) in
collaboration with Management Sciences for Health
(MSH) proposed and launched a pilot program to
improve private drug stores popularly known as “duka la
dawa baridi” and promote them to improved drug shops
known as Accredited Drug Distribution Outlets (ADDO)
popularly known as “duka la dawa muhimu”, which will
be mandated to supply ALU in private sector. Accord-
ingly, most of the 118 drug stores available in Morogoro
Urban District will be improved but in phases. To date,
only 35 (30%) drug stores have been promoted and re-
cent informal survey (data not shown) indicates some of
them continue to sell the subsidized ALU at a higher
price ranging from 1,000–3,000 TShs (0.59–1.76 US$)
instead of the approved 300 TShs (0.18 US$). Besides
ALU being very unpopular (ranked the sixth in the list
of most selling antimalarial drugs in this study) in thePDSUs, high price of other ACTs (Coartem-an ALU sub-
stitute, Duo-cotecxin, Artequine, Artequick and Arco)
has almost driven people to resort to inexpensive but
failed drugs including SP, CQ, malafin, orodar, fansidar
etc. This finding is similar to reports elsewhere [15]
suggesting that unfortunately because of their high
prices, ACTs are not widely accessible to the people who
most need them and many of whom resort to inexpen-
sive but failing drugs such as CQ. In the present study
the effect of price on the accessibility/affordability of
highly efficacious but very costly ACTs were much more
marked in the peri-urban where most of ACTs were not
even stocked by the DSUs serving the area, because, due
to their high cost people could not afford buying them.
This could be explained by difference in socioeconomic
status whereby those residing in the urban centre are
wealthier and hence can afford better but more costly
drugs than their peri-urban counterparts. Similar findings
had been reported previously by [16], who conducted a
community-based survey in Nigeria and demonstrated that
those earning greater than N3000/day were twice as likely
to use “appropriate” drugs (defined as drugs to which
resistance had not developed – Fansidar mainly) compared
to those earning less than N3000/day who were more
likely to use CQ, despite resistance.
Among the concerns of the government regarding the
supply of ALU in the government sector alone, was the
fear that, ALU would find its way and leak to the private
sector. To address this problem, ALU which is supplied
through the government system were uniquely packed in
single dose blisters that were very different from the
Coartem (ALU-alternative that was available in the pri-
vate sector). Notwithstanding, ALU leaked out of gov-
ernment health sector, and in this study, 30% of surveyed
PDSUs in Morogoro urban district were selling ALU
illegally at a slightly higher price ranging from 1,000 to
1,500 TShs (0.59–0.88 US$) compared to 300 TShs (0.18
US$) in the government sector. It is hoped that AMFm
initiative with its subsidy and co-funding approach, if care-
fully monitored for intended services to reach recipients,
will most likely help to save lives and reduce the use of
less-effective malaria treatments by increasing access to
ACTs and displacing artemisinin monotherapies from the
market [17].
In the new era of ACTs, one of the major concerns has
been the possibility that medicine sellers may continue
selling artemisinin derivatives in monotherapy form, po-
tentially jeopardizing ACT efficacy in the long term [9].
In the present study, the government sector was found
selling artemether while the private sector was selling
artemether and cotecxin, both of which are artemisinin
based monotherapies. While the use of artemether may
be explained by the fact that it may likely be used in se-
vere cases of malaria (although the practice need to be
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private sector underscores the need for the education
and other mechanisms to discourage the use of artemisi-
nin based monotherapies to avoid artemisinin resistance;
hence AMFm initiative is expected to play pivotal role
on this.
The knowledge of dispensers regarding the recom-
mended first line malaria treatment was encouraging, al-
though 4% of the 92 dispensers interviewed, did not
know that ALU is the nationally recommended treat-
ment for uncomplicated malaria. Of the 4%, half of them
genuinely confessed to be unaware, while the other half
claimed to know the drug but when requested to name
it, mentioned metakelfin. This proportion may seem to
be small but is very significant, given the number of
people they are serving, raising concerns surrounding
appropriateness of the drugs and information that these
people provide to their customers. The problem of
unskilled medicine sellers is well documented and wide-
spread [18-20], and extensive review of medicine sellers
in eastern African countries of Kenya and Uganda
suggest that, their levels of education vary greatly, but
most have little or no formal training in medicine or
pharmacy [21]. Accordingly, drug shop/outlet/store staff
may be untrained, or trained as medical assistants or
nurses, and even where the official owner or licensee has
health-related qualifications, outlets are often staffed by
less qualified assistants. In the present study, majority
(52%) of drug dispensers were nurses, 20% were medical
doctors/clinical officers, 13% were just drug sellers while
only 15% were pharmacists. Of the drug sellers, 85% had
primary education while only 15% had secondary educa-
tion. Clearly, to achieve a well-regulated and properly
operated private antimalarial selling units, proper licens-
ing accompanied by close supervision and monitoring is
mandatory. Ideally, all antimalarial selling units/outlets
should be manned by a skilled drug dispenser and this
should be a pre-requisite for obtaining a license.
In conclusion, this study has quantified the influence
of high price on the levels, trend and consumption pat-
tern of antimalarial drugs in Morogoro urban district.
The highly efficacious national first line antimalarial drug
ALU was only accessible and affordable for those who
sought medical service through government health sys-
tem at a subsidized price of 300 TShs (0.18 US$) but its
substitute in the private health system (coartem) which
was being sold at a price of about 10,000 TShs (5.9 US$)
per adult dose, was by far unaffordable. Other ACTs
were also sold at similar or close price forcing people to
resort to either inexpensive but failed drugs such
as metakelfin, SP, CQ, malafin, orodar, fansidar or
relatively less expensive artemisinin monotherapies such
as cotecxin and artemether. More than 13% of surveyed
DSUs were manned by unskilled personnel. Althoughthis study was done in Mrogoro urban area, the experi-
ence described is of greater relevance and the results
likely reflect the situation in the whole country although
a further large scale study including the rural area will
give a more representative picture of the entire country.
The study recommends that; since the private sector still
plays a major role in antimalarial drug delivery, and the
current framework of antimalarial drug delivery through
government sector alone has failed to provide sufficient
ACT coverage to make major impact on malaria, it is
inevitable that for successful malaria control effort,
subsidized ACTs should be delivered through both
government and private health system to promote access
and affordability to all who are in need of them. Again,
the current Ministry of Health and Social Welfare idea
of using selected improved private drug shops popularly
known as ADDO will most likely not achieve the highly
needed wider delivery of the much needed ACTs in the
country.
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